ArticleScientific reports2026
UPLC profiling of matcha extract capping biosynthesized copper oxide nanoparticles and their antimicrobial and cytotoxic potentials.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This research demonstrates a green synthesis and subsequent functionalization process of copper oxide nanoparticles (CuO NPs) utilizing matcha green tea extract as a sustainable reducing and functionalizing agent. UPLC-MS analysis revealed the presence of significant bioactive phytochemicals, notably epigallocatechin gallate (EGCG), which is implicated in the reduction process. Thorough characterisation (XRD, FT-IR, SEM) verified the synthesis of pure, crystalline, monoclinic CuO NPs with an average size of 16-24 nm. The nanoparticles had considerable antibacterial activity, exhibiting robust efficacy against Escherichia coli and Staphylococcus aureus, with a minimum inhibitory concentration of 250 µg/ml. CuO NPs-matcha exhibited significant, dose-dependent cytotoxicity against MCF-7 and Caco-2 carcinoma cells, with IC₅₀ values of 122.1 and 161.9 µg/ml, respectively. Crucially, they demonstrated markedly reduced toxicity towards non-cancerous Vero cells (IC₅₀ = 333.2 µg/ml), yielding selectivity indices of 2.73 and 2.06, which confirms a favorable selective profile. Although the positive control doxorubicin showed greater potency (lower IC₅₀), the CuO NPs-Matcha demonstrated significantly higher selectivity for cancer cells, suggesting a potentially improved safety profile despite its lower efficacy. These findings underscore the matcha-synthesized CuO NPs as a highly promising and biocompatible nanomaterial for specific medicinal applications, particularly in antibacterial and anticancer therapies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.